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Clinical impact of artifactual hypoglycaemia and its
diagnosis at the bedside
Rheumatology key message
. Knowledge of artifactual hypoglycaemia is neces-
sary to prevent unnecessary work-up, therapy and
anxiety.
SIR, The term artifactual hypoglycaemia has been pro-
posed for the discrepancy between low capillary and
normal plasma glucose levels, and has been described
in various conditions, including RP [1]. Early recognition
is challenging, but is important to prevent anxiety and un-
necessary treatment and diagnostic tests. We present a
case of artifactual hypoglycaemia in a patient with SSc
and propose a quick method for its diagnosis.
A 57-year-old man was referred from another hospital
because of recurrent, asymptomatic hypoglycaemia. His
medical history included SSc and RP, treated with low-
dose prednisolone, and aortic valve stenosis with
intestinal angiodysplasia for which somatostatin had
been recently started. Subsequent monitoring of capillary
glucose by finger-stick measurements revealed glucose
levels ranging between 2.3 and 7.7 mmol/l, with 15%
of these below 3.5 mmol/l.
Screening diagnostic analysis for insulinoma, per-
formed before the patient was referred, was reportedly
negative. Somatostatin, which was thought to have
caused the low glucose levels, had been discontinued,
the dose of prednisolone was increased (from 5 to
10 mg daily) and continuous feeding over a nasogastric
tube had been initiated. However, none of these interven-
tions had led to a clear, sustainable glucose-increasing
effect (Fig. 1), although his body weight had increased
by 4 kg. The patient had become increasingly anxious
about the apparent treatment resistance of his
hypoglycaemia.
The patient occasionally reported non-specific symp-
toms like blurred vision and tremor that were unrelated
to the capillary glucose level and did not respond to
ingestion of dextrose. We concluded that the criteria
of Whipple’s triad for hypoglycaemia were not met [2]
and suspected a measurement artefact. Because his
sclerosis-affected skin hindered venous access, we
performed simultaneous measurements on the patient’s
earlobe when finger-stick measurement suggested
hypoglycaemia. These measurements revealed glucose
levels to be 2.8 mmol/l higher in earlobe capillary
blood, with none of them being in the hypoglycaemic
range.
Screening for diabetes in people at elevated risk is rou-
tine practice at all levels of clinical care across medical
specialties. Hypoglycaemia in such a patient not treated
with glucose-lowering agents should raise the health care
provider’s suspicion of artifactual hypoglycaemia,
especially when the event is based on capillary blood glu-
cose, measured by finger-stick. Unawareness of this phe-
nomenon may lead to unnecessary diagnostic and
therapeutic interventions, as exemplified in our patient.
Artifactual hypoglycaemia, previously referred to as
pseudo-hypoglycaemia, has been described in patients
with RP, circulatory shock, peripheral arterial disease,
Eisenmenger syndrome, acrocyanosis or hypothermia
[1]. It has been ascribed to reduced perfusion of the per-
ipheral microcirculation with decelerated glucose transit
and increased glucose uptake into the surrounding
tissue [3]. Additionally, the term has also been used to
describe falsely low plasma glucose values resulting
from increased glycolysis by leukocytes, e.g. in chronic
myeloid leukaemia [1, 3]. Diagnosis of artifactual hypogly-
caemia relies on simultaneous glucose measurements in
capillary blood and a venous specimen [1]. Because
venous access can be difficult in patients with SSc be-
cause of their fibrotized skin and stiffened veins, we chose
the earlobe as alternative site for glucose measurement.
Earlobe measurements reflect also capillary blood glu-
cose; however, the earlobe remains unaffected by SSc,
because it lacks connective tissue [4, 5]. In addition, it
allows for diagnosis at the bedside with the same glucose
metre, thus circumventing any differences in accuracy
with laboratory methods.
Our case has potential clinical consequences for pa-
tients with SSc and RP at risk for or having been diag-
nosed with diabetes. Indeed, artifactual normal or lower
than expected finger-stick glucose values in these pa-
tients may give false assumptions of the level of glucose
control in people with (coexistent) diabetes or even refute
its diagnosis, potentially withholding patients from appro-
priate treatment. This phenomenon must be particularly
considered if there is a discrepancy between the haemo-
globin A1c level and glucose values measured by finger-
stick. Whenever frequent glucose monitoring is required,
e.g. with insulin treatment, switching from finger-stick
to earlobe capillary glucose measurement may be
considered.
This case illustrates the importance of awareness of
artifactual hypoglycaemia, not only to avoid unnecessary
work-up and therapy, but also to prevent anxiety asso-
ciated with the belief of having a medical condition that
appears unsolvable. We suggest performing simultaneous
glucose measurements on the patient’s earlobe and
finger-stick whenever this phenomenon is likely to occur,
not only in patients with supposedly hypoglycaemia, but
also in case of lower than expected glucose levels in pa-
tients with (poorly controlled) diabetes mellitus.
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Abatacept concentrations in maternal serum and
breast milk during breastfeeding and an infant
safety assessment: a case study
Rheumatology key message
. Abatacept was secreted into breast milk at levels
1/2001/300 of those in serum.
SIR. The demand for biologic DMARDs has been increasing
in female patients with autoimmune diseases such as RA
who wish to bear children. While women with RA often
show remission during pregnancy, disease exacerbation
is common during the post-partum period [1] and it is there-
fore desirable to ensure that drug treatment is compatible
with breastfeeding. To achieve this goal, more data must
be accumulated about the safety of anti-rheumatic drugs
during pregnancy and breastfeeding [2, 3].
Abatacept is a selective T cell co-stimulation modulator
approved in multiple countries for the treatment of RA. It is
a soluble fusion protein that consists of the extracellular
domain of human cytotoxic T lymphocyteassociated anti-
gen 4 linked to the modified Fc portion of human IgG1 [4].
According to label instructions, abatacept must not be
used in pregnancy unless it is imperative, and women in
childbearing years should apply effective contraceptive
methods throughout treatment and until 14 weeks after
their last abatacept dose [5]. Furthermore, due to insuffi-
cient data, women should avoid breastfeeding throughout
treatment and until 14 weeks after the last abatacept dose
[6, 7]. A EULAR task force also indicated that abatacept
should be avoided during lactation if another therapy is
available to control the disease, but if no other options
are available, then lactation should not be discouraged [8].
FIG. 1 Three-day capillary glucose profile
Three-day capillary glucose profile, while the patient received 10 mg prednisolone and continuous tube feeding, the dose
of which was increased from 1 to 1.5 l per 24 h; other interventions included oral administration of glucose (OG) to
normalize glucose levels.
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